CN Patent

CN107208133A — 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法

Assigned to Janssen Pharmaceutica NV · Expires 2017-09-26 · 9y expired

What this patent protects

本发明涉及用于治疗抑郁症(优选地难治性抑郁症)、用于治疗自杀性患者的抑郁症和/或用于治疗和/或预防自杀倾向(例如自杀意念)的方法和给药方案，所述方法和给药方案包括对患者进行基因分型以确定其BDNF中的Val66Met rs6265多态性，并根据与所述患者的基因型匹配的给药方案施用氯胺酮、优选地艾氯胺酮，优选地鼻内施用艾氯胺酮。

USPTO Abstract

本发明涉及用于治疗抑郁症(优选地难治性抑郁症)、用于治疗自杀性患者的抑郁症和/或用于治疗和/或预防自杀倾向(例如自杀意念)的方法和给药方案，所述方法和给药方案包括对患者进行基因分型以确定其BDNF中的Val66Met rs6265多态性，并根据与所述患者的基因型匹配的给药方案施用氯胺酮、优选地艾氯胺酮，优选地鼻内施用艾氯胺酮。

Drugs covered by this patent

Patent Metadata

Patent number
CN107208133A
Jurisdiction
CN
Classification
—
Expires
2017-09-26
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.